Webcast/Conference Call Information
Celldex management will host a conference call/webcast at 8:30 am ET tomorrow, Monday, November 25, 2013 to discuss the ReACT study results and the rindopepimut program. John F. de Groot, M.D., Associate Professor of the Department of Neuro-Oncology, Director of the Neuro-Oncology Fellowship Program and Director of Clinical Research in the Department of Neuro-Oncology, at the University of Texas MD Anderson Cancer Center in Houston, TX will join the call. Dr. de Groot served on the expert review committee for the ReACT study.
The conference call and presentation will be webcast live over the Internet and can be accessed by logging on to the Events & Presentations section under "Investors and Media" of the Celldex Therapeutics website at www.celldex.com. The call can also be accessed by dialing (866) 743-9666 (within the United States) or (760) 298-5103 (outside the United States). The passcode is 10297215.
A replay of the call will be available for approximately one week after the live call concludes through December 2, 2013. To access the replay, dial 855-859-2056 (within the United States) or 404-537-3406 (outside the United States). The passcode is 10297215.About Rindopepimut Rindopepimut is an investigational immunotherapy that targets the tumor specific oncogene EGFRvIII (v3), a functional and permanently activated variant of the epidermal growth factor receptor (EGFR), a protein that has been well validated as a target for cancer therapy. Expression of EGFRvIII correlates with increased tumorigenicity in mouse models and poor long term survival in clinical studies of patients with glioblastoma (GBM). In addition, EGFRvIII-positive cells are believed to stimulate proliferation of non-EGFRvIII cells through IL-6 cell-to-cell signaling and to release microvesicles containing EGFRvIII, which can merge with neighboring cells, transferring tumor-promoting activity. EGFRvIII expression may also be associated with tumor stem cells that have been identified in GBM. These stem cells contribute to resistance to cytotoxic therapy and tumor recurrence. EGFRvIII is expressed in tumors in about 30% of patients with GBM. It has not been detected at a significant level in normal tissues; therefore, targeting of this tumor-specific molecule is not likely to impact healthy tissues.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts